EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to six new employees for an aggregate of 20,000 shares.

The options were granted on March 13, 2026 at an exercise price of $13.20 (closing price that day), have a 10-year term and vest over four years (25% after one year, then monthly).

Key Figures

Inducement option grant: 20,000 shares New employees: 6 employees Exercise price: $13.20 per share +3 more

6 metrics

Inducement option grant 20,000 shares Aggregate non-statutory stock options to six new employees

New employees 6 employees Recipients of inducement stock option awards

Exercise price $13.20 per share Option exercise price, equal to Mar 13, 2026 closing price

Option term 10 years Duration of the inducement stock options

Vesting period 4 years 25% at first anniversary, remainder monthly over 3 years

Initial vesting tranche 25% Portion of shares vesting on first anniversary of grant date

Market Reality Check

Price: $13.20 Vol: Volume 1,222,777 is below...

low vol

$13.20 Last Close

Volume Volume 1,222,777 is below the 20-day average of 2,032,620, indicating lighter-than-normal trading. low

Technical Price at 13.20 is trading above the 200-day MA of 12.99 despite a -5.92% daily move.

Peers on Argus

EYPT fell 5.92% while peers like QURE (-7.72%) and OCS (-5.81%) also declined, w...

EYPT fell 5.92% while peers like QURE (-7.72%) and OCS (-5.81%) also declined, with all five listed peers negative, suggesting a broader biotech/ophthalmology downdraft alongside the company-specific grant news.

Historical Context

5 past events · Latest: Mar 04 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Earnings results	Negative	-1.8%	Weaker 2025 revenue and wider net loss alongside higher operating expenses.
Mar 02	Phase 3 dosing	Positive	+4.4%	First patients dosed in two global Phase 3 DME trials of DURAVYU.
Feb 25	Earnings date announcement	Neutral	+4.2%	Scheduled Q4 and full-year 2025 results call for Mar 4, 2026.
Feb 24	Investor conferences	Neutral	-0.1%	Planned participation in four March investor conferences and webcasts.
Feb 18	Executive appointment	Positive	-3.7%	Appointment of a new CCO plus a 175,000-option inducement award.

Pattern Detected

Recent news often aligned with price moves; one positive executive appointment drew a negative reaction.

Recent Company History

This announcement follows a busy period for EyePoint. On Mar 4, 2026, the company reported Q4 and full-year 2025 results, highlighting $306 million in cash and a runway into Q4 2027, but also a $232.0M net loss and lower $31.4M revenue versus $43.3M in 2024. On Mar 2, 2026, first patients were dosed in two global Phase 3 DME trials, with topline data expected in 2H 2027. A new CCO was appointed on Feb 18, 2026 with a 175,000-option inducement grant, showing ongoing build-out ahead of potential DURAVYU launches. Today’s smaller inducement grants continue that hiring pattern.

Market Pulse Summary

This announcement details a modest inducement grant of 20,000 non-statutory stock options to six new...

Analysis

This announcement details a modest inducement grant of 20,000 non-statutory stock options to six new employees at an exercise price of $13.20 per share, vesting over 4 years with a 10-year term. It follows earlier, larger inducement awards tied to senior hires and comes as EyePoint advances multiple Phase 3 DURAVYU programs and manages a widened $232.0M annual net loss. Investors may focus more on upcoming Phase 3 readouts, cash runway to Q4 2027, and execution on commercialization plans.

Key Terms

non-statutory stock options, nasdaq listing rule 5635(c)(4), exercise price, vesting, +1 more

5 terms

non-statutory stock options financial

"the Company granted non-statutory stock options to new employees as inducement"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The option awards have an exercise price of $13.20 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options have a ten-year term and vest over four years, with 25% of the"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

inducement awards financial

"granted non-statutory stock options to new employees as inducement awards outside"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 20,000 shares of EyePoint common stock to six new employees. The stock options were granted on March 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $13.20 per share, the closing price of EyePoint’s common stock on March 13, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Green Room Communications
Direct: 850-384-2833
EyePointMedia@grcomms.com

FAQ

What did EyePoint (EYPT) disclose on March 16, 2026 about inducement grants?

EyePoint granted non-statutory options for up to 20,000 shares to six new employees on March 13, 2026. According to the company, the grants were approved by the Compensation Committee as inducement awards under NASDAQ Listing Rule 5635(c)(4), using the March 13 closing price.

What is the exercise price and term of the EYPT inducement options granted March 13, 2026?

The options carry an exercise price of $13.20 and a ten-year contractual term. According to the company, $13.20 was the closing price on March 13, 2026, and each option expires ten years from its grant date if not exercised.

How do the EYPT inducement option grants vest for new employees?

The options vest over four years with a 25% vesting cliff after one year, then monthly thereafter. According to the company, vesting requires continued service through each applicable vesting date for the remainder of the four-year schedule.

How many employees received inducement awards and what is the aggregate share amount for EYPT?

Six new employees received inducement option awards covering an aggregate of 20,000 shares. According to the company, these awards were granted as material inducements tied to each employee entering employment with EyePoint.

Will the EYPT inducement options affect shares outstanding or cause dilution when exercised?

The options are potentially dilutive to shareholders if exercised because they cover 20,000 shares in aggregate. According to the company, the awards are standard stock options that will increase outstanding shares only upon exercise by the holders.